NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 74 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $10,605,000 | -2.9% | 364,800 | +1.2% | 0.23% | -0.4% |
| Q4 2020 | $10,921,000 | +90.4% | 360,500 | +0.0% | 0.23% | +58.9% |
| Q3 2020 | $5,735,000 | -18.7% | 360,454 | +0.9% | 0.15% | -24.7% |
| Q2 2020 | $7,055,000 | +63.0% | 357,409 | +1.8% | 0.19% | +8.4% |
| Q1 2020 | $4,329,000 | -33.3% | 351,100 | 0.0% | 0.18% | -12.7% |
| Q4 2019 | $6,492,000 | +33.5% | 351,100 | 0.0% | 0.20% | +5.7% |
| Q3 2019 | $4,863,000 | -5.4% | 351,100 | 0.0% | 0.19% | +4.3% |
| Q2 2019 | $5,140,000 | – | 351,100 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 16,245,817 | $247,749,000 | 45.93% |
| Ponoi II Management, LLC | 1,298,908 | $19,808,000 | 43.96% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $57,442,000 | 39.74% |
| Ponoi Management, LLC | 1,298,908 | $19,808,000 | 25.71% |
| Euclidean Capital LLC | 746,674 | $11,387,000 | 6.62% |
| StepStone Group LP | 1,573,357 | $23,994,000 | 1.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,494 | $3,058,000 | 1.26% |
| First Light Asset Management, LLC | 816,653 | $12,454,000 | 1.10% |
| BVF INC/IL | 955,000 | $14,564,000 | 0.58% |
| HighVista Strategies LLC | 46,243 | $705,000 | 0.45% |